Evidence map›Paper›PMID 22553998›Full record

ArticleChemical biology & drug design2012

Enhancing and limiting endothelin-1 signaling with a cell-penetrating peptide mimicking the third intracellular loop of the ETB receptor.

Christine O Sallum, Jamie L Wilson, Chamila Rupasinghe, Eric Berg, Jun Yu, Daniel S Green, Linda Taylor, Dale Mierke, Peter Polgar

Open access · bronzeAbstract read
In one paragraph

Article in Chemical biology & drug design, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. C-terminus of ETA/ETB receptors regulate endothelin-1 signal transmission.Journal of peptide science : an official publication of the European Peptide Society · 2013
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Christine O SallumDepartment of Biochemistry, Boston University School of Medicine, MA 02118, USA.
Jamie L Wilson
Chamila Rupasinghe
Eric Berg
Jun Yu
Daniel S Green
Linda Taylor
Dale Mierke
Peter Polgar
Boston University · USDartmouth College · US21st Century Oncology (United States) · US

Funding

REGULATION OF PROSTAGLANDIN SYNTHESIS BY LUNG CELLSR01HL025776 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI POLGAR, PETER RUDOLPH · 1985 to 2013
$4.6M
PRE- AND POSTDOCTORAL TRAINING IN BIOCHEMISTRY OF AGINGT32AG000115 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI POLGAR, PETER RUDOLPH · 1985 to 2012
$4.3M
NHLBI NIH HHS R01 HL025776NHLBI NIH HHS R01-HL-025776NHLBI NIH HHS R01-HL-025776-25S1NIA NIH HHS T32 AG000115NIA NIH HHS T32-AG-000115
6 · The paper itself

Abstract

TAT (a 13-mer derived from the HIV-1 Tat protein)-linked cell-permeable peptides deliver plasma membrane impermeable cargos into the cell. We investigated the effect of a TAT-linked intracellular third loop of the endothelin-1 type B receptor on endothelin-1 activation of ERK. The effect of this peptide on ERK activation was determined in ETB receptor cDNA-transfected Chinese hamster ovary cells and in ETA- and ETB-expressing human pulmonary artery smooth muscle cells obtained from a normal and a bone morphogenetic protein-2 receptor, exon 1-8 deletion subject, with pulmonary hypertension. In the Chinese hamster ovary cells the peptide, at optimum 10 μm concentration, suppressed endothelin-1 activation. In the normal human pulmonary artery smooth muscle cells, the peptide marginally enhanced endothelin-1 activation of ERK. However, it markedly enhanced the endothelin-1 activation of ERK in the bone morphogenetic protein-2 receptor human pulmonary artery smooth muscle cells. While the effective concentration for endothelin-1 activation of ERK remained unchanged in the bone morphogenetic protein-2 receptor human pulmonary artery smooth muscle cells, the number of ETB receptors declined by 2/3. These data point to the intracellular third loop peptide as having variable receptor interactive effects with both signal repressive and enhancing capabilities. Peptides that can alter endothelin-1 signal capabilities are potentially important in the study and treatment of pulmonary hypertension.

Indexed as

Amino Acid SequenceAnimalsBone Morphogenetic Protein Receptors, Type IICell-Penetrating PeptidesCells, CulturedCHO CellsCricetinaeEndothelin-1Extracellular Signal-Regulated MAP KinasesGene Products, tatHumansMAP Kinase Signaling SystemMolecular Sequence DataMyocytes, Smooth MuscleProtein ConformationPulmonary ArteryBMPR2 protein, humanBone Morphogenetic Protein Receptors, Type IICell-Penetrating PeptidesEndothelin-1Extracellular Signal-Regulated MAP KinasesGene Products, tatReceptor, Endothelin AReceptor, Endothelin B

Identifiers

PMID22553998
PMCPMC3496424
OpenAlexW1577177737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.